Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02909946
Other study ID # R01AG041780
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 15, 2016
Est. completion date August 29, 2018

Study information

Verified date September 2018
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multidrug-resistant organisms (MDROs) are endemic in nursing homes (NHs) with prevalence rates surpassing those in hospitals. The aim of the study is to design and evaluate the effectiveness of a multi-component intervention to reduce new acquisition of MDROs in NH residents. The intervention will incorporate resident-level, environmental, and caregiver based strategies. Using a cluster-randomized study design, three NHs will be randomized to the intervention group and three to the control group. Control NHs will be allowed to continue standard infection prevention practices. Nursing homes will serve as the unit of allocation. Analyses will be performed both at the resident and the cluster level. The primary outcomes of the study are reduction in MDRO prevalence, and reduction in new MDRO acquisition .


Description:

The NH intervention will incorporate resident-level, environmental, and caregiver based strategies, including: a. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for healthcare workers (HCW) when providing activities of daily living (ADL) assistance for residents at highest-risk (caregiver intervention); b. Hand hygiene education to residents and families (resident-level intervention); c. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention); d. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention); e. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection preventionists, front-line healthcare personnel, and facility leadership (facility intervention).


Recruitment information / eligibility

Status Completed
Enrollment 246
Est. completion date August 29, 2018
Est. primary completion date August 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years old

- Residing in a participating NH facility

- Provided informed consent for participation

Exclusion Criteria:

- Receiving end-of-life care

- Non-English language speaking

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Multi-modal Infection Control Program
Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention). Hand hygiene education to residents and families (resident-level intervention). Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention). Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention). Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention).

Locations

Country Name City State
United States University of Michigan and partner nursing homes Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence density of multidrug-resistant organisms (MDRO) Total number of MDROs isolated across all MDROs and all anatomic sites for all enrolled residents over the duration of the study period From enrollment up to 6 months of study followup, or until study withdrawal (discharged from facility, at resident request, death)
Secondary Incidence of multidrug-resistant organisms (MDRO) Total number of MDROs newly acquired (resident not colonized at baseline) isolated across all MDROs for all enrolled residents over the duration of the study period From enrollment up to 6 months of study followup, or until study withdrawal (discharged from facility, at resident request, death)
Secondary Incidence of healthcare-associated infections Total number of new infections acquired at the nursing home for all enrolled residents over the duration of the study period From enrollment up to 6 months of study followup, or until study withdrawal (discharged from facility, at resident request, death)
See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Recruiting NCT04181112 - Fecal Transplant for MDRO Decolonization N/A
Completed NCT05048693 - Use of New Antibiotics in Sweden
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Completed NCT04212130 - Can Environmental Cleanliness be Assessed by BCA (Bicinchoninic Acid) Method N/A
Completed NCT05100407 - Factors Impacting the Prevalence of MDR Bacteria
Completed NCT05549427 - Ventilator Associated Pneumonia by Multi-Drug Resistant Organism
Not yet recruiting NCT06370299 - Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
Recruiting NCT06148480 - Perinatal Transmission of MDR Bacteria
Recruiting NCT04995133 - Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs. Phase 4
Recruiting NCT03921645 - Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia N/A
Completed NCT06199141 - Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)
Recruiting NCT04759001 - FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae Phase 1/Phase 2
Not yet recruiting NCT05791396 - FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae Phase 1/Phase 2
Terminated NCT02906774 - Fecal Transplant for MDR Pathogen Decolonization
Recruiting NCT06036628 - Resistant Bacteria in Children in France